Fulcrum Therapeutics (FULC) Non-Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Non-Current Assets for 9 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Non-Current Assets fell 88.37% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $27.0 million (down 35.52% YoY), while the FY2025 annual figure was $8.8 million, down 18.44% from the prior year.
• Non-Current Assets eased to $1.1 million in Q2 2026 per FULC's latest filing, from $8.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $21.0 million in Q2 2022 and bottomed at $1.1 million in Q2 2026.
• Historically, Non-Current Assets has averaged $13.6 million across 5 years, with a median of $14.3 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 124.02% — and 2026, when it plunged 88.37%.
• Fulcrum Therapeutics' Non-Current Assets stood at $19.2 million in 2022, then decreased by 19.15% to $15.5 million in 2023, then tumbled by 30.33% to $10.8 million in 2024, then decreased by 18.44% to $8.8 million in 2025, then slumped by 87.49% to $1.1 million in 2026.
• Business Quant data shows FULC's Non-Current Assets at $1.1 million in Q2 2026, $8.1 million in Q1 2026, and $8.8 million in Q4 2025.